Takara Bio Inc. (TYO:4974)

Revenue by Segment

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
Drug Discovery Company	45.04B	43.51B	78.14B	67.70B	46.09B
Drug Discovery Company Growth	3.53%	-44.33%	15.43%	46.90%	-
Total	45.04B	43.51B	78.14B	67.70B	46.09B
Total Growth	3.53%	-44.33%	15.43%	46.90%	33.34%

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
Japan	15.06B	15.43B	45.67B	34.08B	20.48B
Japan Growth	-2.41%	-66.20%	34.02%	66.43%	38.31%
United States of America	13.00B	12.97B	12.89B	10.19B	7.86B
United States of America Growth	0.18%	0.68%	26.51%	29.56%	-1.86%
China	8.52B	7.04B	10.80B	11.91B	8.42B
China Growth	21.07%	-34.82%	-9.31%	41.51%	31.67%
Asia Excluding Japan and China	2.86B	3.36B	3.55B	6.61B	4.92B
Asia Excluding Japan and China Growth	-14.90%	-5.39%	-46.39%	34.51%	161.96%
Europe	5.25B	4.50B	4.95B	4.67B	3.74B
Europe Growth	16.73%	-9.15%	6.02%	24.71%	16.71%
Others	353.00M	205.00M	293.00M	244.00M	671.00M
Others Growth	72.20%	-30.03%	20.08%	-63.64%	147.60%
Total	45.04B	43.50B	78.14B	67.70B	46.08B
Total Growth	3.53%	-44.33%	15.43%	46.90%	33.34%

Source: S&P Global Market Intelligence.